TPST
NASDAQ
$0.95
Tempest Therapeutics Inc (TPST)
Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Target: $11 (+1054.98%)
Market Cap
$15M
Price Chart
Valuation
Market Cap$15M
P/B19.20
Profitability
EBITDA-$43M
EPS-$5.31
Growth & Risk
FCF 5Y CAGR+0.25%
Sharpe Ratio-1.33